CEPHALEXIN Drug Patent Profile

Name: CEPHALEXIN Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Cephalexin, and what generic alternatives are available?

Cephalexin is a drug marketed by Ajenat Pharms, Alkem Labs Ltd, Anda Repository, Apothecon, Aurobindo Pharma, Barr, Chartwell Rx, Facta Farma, Hikma, Ivax Sub Teva Pharms, Lupin, Purepac Pharm, Stevens J, Sun Pharm Inds (in), Sun Pharm Inds Ltd, Teva, Yoshitomi, Hikma Pharms, Vitarine, Yung Shin Pharm, and Aurobindo Pharma Ltd. and is included in fifty-one NDAs.

The generic ingredient in CEPHALEXIN is cephalexin. There are twenty-nine drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the cephalexin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cephalexin

A generic version of CEPHALEXIN was approved as cephalexin by TEVA on February 13^th, 1987.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for CEPHALEXIN?
What are the global sales for CEPHALEXIN?
What is Average Wholesale Price for CEPHALEXIN?

Summary for CEPHALEXIN

US Patents:	0
Applicants:	21
NDAs:	51
Finished Product Suppliers / Packagers:	36
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	66
Drug Prices:	Drug price information for CEPHALEXIN
Drug Sales Revenues:	Drug sales revenues for CEPHALEXIN
What excipients (inactive ingredients) are in CEPHALEXIN?	CEPHALEXIN excipients list
DailyMed Link:	CEPHALEXIN at DailyMed

Drug patent expirations by year for CEPHALEXIN

Recent Clinical Trials for CEPHALEXIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Helsinki University Central Hospital	PHASE1
University of Helsinki	PHASE1
Aleksi Tornio	PHASE1

See all CEPHALEXIN clinical trials

Pharmacology for CEPHALEXIN

Drug Class	Cephalosporin Antibacterial

Medical Subject Heading (MeSH) Categories for CEPHALEXIN

Anti-Bacterial Agents

US Patents and Regulatory Information for CEPHALEXIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Yung Shin Pharm	CEPHALEXIN	cephalexin	FOR SUSPENSION;ORAL	065336-002	Jul 25, 2007	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Teva	CEPHALEXIN	cephalexin	CAPSULE;ORAL	062702-002	Feb 13, 1987	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Stevens J	CEPHALEXIN	cephalexin	CAPSULE;ORAL	062870-001	Mar 17, 1988		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Apothecon	CEPHALEXIN	cephalexin	FOR SUSPENSION;ORAL	062987-001	Jul 25, 1989		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Lupin	CEPHALEXIN	cephalexin	FOR SUSPENSION;ORAL	065234-002	Aug 17, 2005	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Yoshitomi	CEPHALEXIN	cephalexin	CAPSULE;ORAL	062871-001	Jul 5, 1988		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Barr	CEPHALEXIN	cephalexin	FOR SUSPENSION;ORAL	062778-001	Aug 6, 1987		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Market Overview and Financial Trajectory for Cephalexin

Last updated: February 13, 2026

Cephalexin, a first-generation cephalosporin antibiotic, addresses bacterial infections including respiratory tract, skin, and urinary tract infections. Market dynamics are driven by antimicrobial resistance concerns, prescription patterns, and manufacturing trends, impacting revenue and investment in this sector.

What Are the Key Market Drivers for Cephalexin?

Increasing Incidence of Bacterial Infections

Global bacterial infection rates remain high due to worsening hygiene conditions and antibiotic resistance, spurring consistent demand for cephalexin. The prevalence of skin infections, especially in developing regions, supports steady consumption.

Prescriptive Guidelines and Clinical Adoption

Clinical protocols favor cephalexin for uncomplicated infections due to its efficacy, low cost, and safety profile. It remains a first-line agent in many countries for skin and soft tissue infections.

Antibiotic Resistance and Market Competition

Resistance to broader-spectrum antibiotics shifts prescriber preference toward older, accessible drugs like cephalexin, although resistance development poses future challenges.

Manufacturing and Supply Chain Factors

Large pharmaceutical companies, including Teva, Sandoz, and pharmacy chains, produce generic cephalexin, ensuring affordability and wide distribution. Regulatory approvals in emerging markets expand availability.

Impact of COVID-19 Pandemic

The pandemic disrupted routine healthcare access but also heightened demand for antibiotics in bacterial coinfections, temporarily boosting cephalexin sales, especially in regions with strained healthcare systems.

How Is the Market for Cephalexin Structured?

Segments	Characteristics
Geographic Markets	North America, Europe, Asia-Pacific, Latin America. Driven by prescription rates and healthcare access.
Formulations	Oral capsules, tablets, suspensions. Oral forms dominate due to ease of administration.
End-user	Hospitals, retail pharmacies, clinics. Retail and wholesale channels are primary distribution points.
Competition	Predominantly generics from multiple manufacturers. Few patented formulations; brand presence limited.

What Are the Financial Trends and Projections?

Market Valuation and Growth Rates

Year	Global Market Size (USD billion)	CAGR (2018-2025)	Notes
2020	0.8	—	Market constrained by resistance and generic prevalence.
2021	0.83	2.5%	Slight growth driven by increased bacterial infections.
2022	0.86	3.6%	Post-pandemic demand stabilizes, market expands.
2023	0.89	3.0%	Continued growth, steady supply chain.
2025 (projected)	1.02	—	Expected to reach over $1 billion in global sales.

Revenue Breakdown by Region (2022)

North America: 35%
Europe: 25%
Asia-Pacific: 30%
Latin America: 10%

This distribution reflects prescription practices, healthcare infrastructure, and economic factors, with Asia-Pacific showing the fastest growth due to expanding healthcare access.

Key Players and Revenue Contributions

Company	Market Share	Revenue (USD millions)	Remarks
Teva Pharmaceuticals	25%	213	Largest producer of generic cephalexin.
Sandoz	20%	170	Extensive distribution networks.
Other generics	55%	470	Numerous regional manufacturers.

What Are the Challenges and Opportunities?

Challenges

Growing resistance reduces clinical effectiveness over time.
Price erosion from generic competition compresses profit margins.
Regulatory hurdles and quality control issues, especially in emerging markets.

Opportunities

Formulation developments, such as sustained-release or combination therapies, can extend product life cycles.
Expanding access in emerging markets due to increasing healthcare spending.
Strategic alliances for supply chain resilience and cost reduction.

How Will Market Dynamics Evolve?

Resistant bacterial strains may diminish cephalexin’s clinical utility, necessitating innovation or combination therapies. Increasing global healthcare expenditure and better diagnostic capabilities will sustain demand. Nevertheless, competition from newer antibiotics and shifts toward narrow-spectrum agents could limit long-term growth.

Competitive pressures will drive price decreases. Investments in manufacturing efficiencies and regional regulatory compliance will be vital for maintaining margins. Emerging markets present opportunities for growth, with regional manufacturers expanding capacity.

Key Takeaways

Cephalexin remains a staple in uncomplicated bacterial infection treatment.
The global market hit approximately $0.89 billion in 2022, with a projected CAGR of 3% through 2025.
North America and Europe dominate due to established healthcare infrastructure; Asia-Pacific shows rapid growth.
Market challenges include antibiotic resistance, generic competition, and regulatory hurdles.
Opportunities exist in formulation innovation and market expansion into emerging economies.

Frequently Asked Questions

1. What factors could hinder cephalexin’s market growth?
Resistance development diminishes clinical utility; price competition and regulatory challenges also impact profitability.

2. Which regions are expected to drive future growth?
Asia-Pacific and Latin America, due to expanding healthcare infrastructure and rising bacterial infection rates.

3. How does resistance impact cephalexin’s usage?
Increased resistance limits its effectiveness, leading clinicians to switch to newer or broader-spectrum antibiotics.

4. What are key regulatory considerations?
Manufacturers must ensure compliance with Good Manufacturing Practices (GMP) and secure approvals from agencies like the FDA and EMA, especially for generic formulations.

5. Are there innovations in cephalexin formulations?
Limited, but some research explores combination therapies and sustained-release formulations to extend efficacy and improve patient adherence.

References

MarketResearch.com, "Global Cephalexin Market," 2023.
Grand View Research, "Antibiotics Market Size, Share & Trends," 2022.
World Health Organization, "Antibacterial Resistance Threats," 2021.
IQVIA, "Global Antibiotics Market Data," 2022.
U.S. Food and Drug Administration, "Generic Drug Approvals," 2023.

More… ↓

⤷ Start Trial